


# Innovative Medicines Initiative

# IMI – Europe's partnership for health




# Goals of IMI 2 programme

- **Increase the success rate of clinical trials** of new medicines & vaccines
- **Speed up the earlier stages** of drug development
- **Develop new treatments** for areas of **unmet need**
- **Develop new biological markers** to **diagnose** diseases and **assess** treatments
- **Improve the drug development process** by creating tools to assess the efficacy, safety and quality of medicines

# The IMI community

63 projects → > 8000 researchers



**61%** of projects reported some form of **PATIENT INVOLVEMENT**


**REGULATORS ON BOARD OF**  
**12**  
**PROJECTS**

**50%** of projects have **REGULATORY AUTHORITIES** representatives in Scientific Advisory Boards

# Ongoing IMI projects



Publically available toxicology data



Searchable in a database

Species	Strain	Sex	Age at Start of Treatment	Age Unit	Dosage	Vehicle
Rat	Sprague-Dawley	Male and female	6	Weeks	0 mg/kg; 20 mg/kg	Feed

Timepoint	Timepoint Unit	Dose (mg/kg)	Sex	Number of Animals Affected	Total Number of Animals	Gross Pathology Organ Affected
97	Days	0	Male	1	10	Lung
97	Days	0	Male	1	10	Kidney
97	Days	0	Male	1	10	Kidney
97	Days	0	Female	0	10	Lung
97	Days	0	Female	0	10	Kidney
97	Days	0	Female	0	10	Kidney
97	Days	0	Female	0	10	Kidney
97	Days	20	Male	0	10	Lung
97	Days	20	Male	0	10	Kidney

Predictive *in-silico* models

Reports from **efpia** companies

# IMI's drug discovery platforms

**European Lead Factory Focus:**  
identification of new hits

**ELF Budget:**

▪ €196 million

[europeanleadfactory.eu](http://europeanleadfactory.eu)

'Qualified'  
hit



Lead   Clinical candidate   Phase 1 ready

**ENABLE Budget:**

▪ €101 million

[nd4bb-enable.eu](http://nd4bb-enable.eu)

**ENABLE focus:** to move promising hits into early clinical development

# IMI2 Strategic Research Agenda

Comprehensive framework  
for a 10-year programme

Prepared with input from  
80+ organisations

Project ideas from industry  
and third parties will be  
screened against it

<http://goo.gl/jqMP9g>



The right prevention and treatment  
for the right patient at the right time

Strategic Research Agenda for  
Innovative Medicines Initiative 2



**efpia**  
European Federation of Pharmaceutical  
Industries and Associations

**V** Vaccines Europe  
An industry for healthy lives

**ebe**  
European  
biopharmaceutical  
enterprises

**imi**  
Innovative Medicines Initiative

**imi** | innovative  
medicines  
initiative



# 7 priority themes and enablers

## IMI2 scientific programme: the need for focus

### Therapeutic Areas and Cross-cutting Themes

- 1. Neuro-degeneration**
  - Successfully prevent and treat dementia and other neurodegenerative diseases
- 2. Prevention and treatment of immune-mediated disease**
  - Advance immunological understanding to deliver new treatments and develop new and better vaccines for non-infectious diseases
- 3. Metabolic disorders**
  - Tackle all phases of disease and its complications, including prevention and early interception
- 4. Infection control**
  - Address multidrug resistance and create incentives for reinvestment (including antimicrobials, antivirals, vaccines) and develop new and better prophylactic vaccines
- 5. Translational Safety**
  - Identification of predictors of safety and development of point of care for safety biomarkers and development of new human biology platform to predict toxicity and safety during early drug development


### Differentiating Enablers for all themes

#### Towards early and effective patient access to innovative prevention and treatment solutions (Medicines Adaptive Pathways to Patients):


- Target validation based on human biology
- Stratified medicine, precision medicine
- Innovation in clinical trials
- Data generation and interpretation (knowledge management)
- Prevention, disease interception, patient adherence (incl. societal acceptance of vaccines)
- Effect on medical practice and outcomes (health/disease management)
- Regulatory framework (including pharmacovigilance)
- Patient access

- \* Neuro-degeneration
- \* Immune-Mediated diseases
- \* Metabolic Disorders
- \* Infection control
- \* Translational safety
- \* Medicines Adaptive Pathways to Patients
- \* Data generation and exploitation


# IMI 2 life cycle




# EoI Participants Success Rates



# IMI Funding




# Participation and Funding by Organisation Type



- SME
- Academic and Research
- Regulator
- Patient Organisation
- EFPIA
- Other

### IMI Funding (€ million)



# Top 20 Beneficiaries

Organisation	Country	Projects	Funding
Institut National de la Santé et de la Recherche Médicale	France	22	€71,031,446
London School of Hygiene and Tropical Medicine	United Kingdom	5	€59,419,008
Centre Hospitalier Universitaire de LIMOGES	France	3	€43,295,622
Uppsala Universitet	Sweden	9	€37,666,409
The Chancellor, Masters and Scholars of the University of Oxford	United Kingdom	17	€33,586,016
Universitair Medisch Centrum Utrecht	Netherlands	5	€33,543,912
University of Dundee	United Kingdom	6	€20,920,436
Karolinska Institutet	Sweden	16	€19,513,599
Pivot Park Screening Centre BV	Netherlands	1	€17,182,800
World Vision of Ireland	Ireland	1	€15,284,473
UNIVERSITEIT ANTWERPEN	Belgium	7	€15,119,479
Université de Genève	Switzerland	11	€13,046,442
The University of Edinburgh	United Kingdom	7	€13,013,811
King's College London	United Kingdom	9	€12,306,705
Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.	Germany	7	€11,324,390
European Clinical Research Infrastructure Network	France	1	€11,311,611
Stichting VU-VUmc	Netherlands	13	€11,242,543
Bristol University	United Kingdom	2	€10,674,001
Imperial College London	United Kingdom	9	€10,365,553

# Future IMI Calls - Timelines & info

- Find out more: <http://bit.ly/futuretopics>
- Call launch: Summer 2015

**Disclaimer - All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be communicated after approval by the IMI Governing Board.**

# Future IMI Calls - Indicative topics – 1/2

- **Inflammation and Alzheimer's disease (AD):** modulating microglia function – focussing on TREM2 and CD33
- Understanding the role of **amyloid biomarkers** in diagnosis, clinical management and treatment of patients with **cognitive impairment**
- Evolving models of **patient engagement** and access for earlier identification of **Alzheimer's disease**
- Bringing **apolipoprotein E (APOE)** biology to validated **Alzheimer's disease** targets



# Future IMI Calls - Indicative topics – 2/2

- **Patient perspective** elicitation on **benefits and risks** of medicinal products, supplementing benefit risk assessments by regulators and HTAs (health technology assessments) from development through the entire life cycle
- **Diabetic kidney disease (DKD)** biomarker idea

# Stay in touch

- Visit our website  
[www.imi.europa.eu](http://www.imi.europa.eu)
- Sign up to our newsletter  
[bit.ly/IMInewsletter](http://bit.ly/IMInewsletter)
- Follow us on Twitter  
[@IMI\\_JU](https://twitter.com/IMI_JU)
- Join our LinkedIn group  
[bit.ly/LinkedInIMI](http://bit.ly/LinkedInIMI)
- E-mail us  
[infodesk@imi.europa.eu](mailto:infodesk@imi.europa.eu)



- Home
- About IMI
- Ongoing projects
- Calls for proposals
- News, Events & Media
- Reference documents

- PARTNER SEARCH
- EDUCATION & TRAINING
- SMALL & MEDIUM-SIZED ENTERPRISES
- INTELLECTUAL PROPERTY

**THE INNOVATIVE MEDICINES INITIATIVE**  
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.  
IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.  
IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.

**IMI LAUNCHES EBOLA+ PROGRAMME**  
IMI has launched an ambitious programme to accelerate the development of **vaccines and treatments** against **Ebola and related diseases**. The first Call under the Ebola+ programme has a total budget of €280m.

**IMI NEWSFLASH**  
**10/11/2014** : Got questions about IMI's #Ebola programme? Check the FAQs and sign up to our webinars on 12/11 and 17/11 <http://t.co/gaZFnWZk1a>  
**06/11/2014** : IMI #Ebola Topic 5: rapid #diagnostic tests that work in the real world <http://t.co/gaZFnWZk1a>  
**06/11/2014** : IMI #Ebola Topic 4: using technology to promote #vaccine compliance <http://t.co/gaZFnWZk1a>

**NEWSLETTER**  
[Read & subscribe](#) [more](#)

**AGENDA**

- 03/12/2014 - C-Path and IMI 2nd Annual Meet...
- 26/11/2014 - Bringing health-related life s...
- 18 - 18/11/2014 - Financial Management Workshop ...





**Thank you**

Colm Carroll  
colm.carroll@imi.europa.eu

[www.imi.europa.eu](http://www.imi.europa.eu)  
 @IMI\_JU